Eckelman Brendan P. 4
4 · Inhibrx, Inc. · Filed May 24, 2024
Insider Transaction Report
Form 4
Inhibrx, Inc.INBX
Eckelman Brendan P.
DirectorChief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-05-22$34.12/sh−2,510$85,641→ 6,667 totalExercise: $33.63Exp: 2031-01-15→ Common Stock (2,510 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-05-22$34.12/sh−2,500$85,300→ 26,667 totalExercise: $23.30Exp: 2033-01-03→ Common Stock (2,500 underlying)
Footnotes (2)
- [F1]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
- [F2]Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 3, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.